10X Genomics, Inc. (TXG)

Market Cap	3.23B
Revenue (ttm)	497.93M
Net Income (ttm)	-142.49M
Shares Out	113.91M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,344
Open	28.96
Previous Close	28.48
Day's Range	27.51 - 29.04
52-Week Range	27.51 - 187.85
Beta	1.70
Analysts	Buy
Price Target	56.21 (+98.4%)
Earnings Date	Nov 1, 2022

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me...

• Industry: Life Sciences Tools & Services
• IPO Date: Sep 12, 2019
• CEO: Serge Saxonov
• Employees: 1,239
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG

Full Company Profile

Financial Performance

In 2021, 10X Genomics's revenue was $490.49 million, an increase of 64.13% compared to the previous year's $298.85 million. Losses were -$58.22 million, -89.27% less than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is 56.21, which is an increase of 98.41% from the latest price.

Price Target

$56.21

(98.41% upside)

Analyst Consensus: Buy

Stock Forecasts